Abbott India inks pact with Novo Nordisk India to launch Extensior

27 Feb 2026 Evaluate

Abbott India has entered into strategic collaboration with Novo Nordisk India to commercialize Extensior for people living with type 2 diabetes. This partnership leverages Novo Nordisk’s scientific leadership in GLP-1s and Abbott’s strong distribution network to expand access in India to a high-quality, evidence-based diabetes therapy, beyond regions Novo Nordisk currently serves. Extensior is a second brand of Ozempic, the world’s most prescribed GLP-1 RA (receptor agonist) molecule.

Extensior is approved as an adjunct to diet and exercise for adults with type 2 diabetes and is a GLP-1 RA recognized for offering the broadest range of benefits for people with this condition. Semaglutide, the molecule in Extensior, has demonstrated powerful HbA1c reduction, compelling weight-loss benefits, and proven risk reduction of cardiovascular and kidney events in people with type 2 diabetes. 

Abbott India is one of the leading multinational pharmaceutical companies in India and operates with owned manufacturing units and various independent contract/third party manufacturers based across the country. The company sells its products through independent distributors primarily within India.


Abbott India Share Price

26495.15 159.45 (0.61%)
27-Feb-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1738.10
Dr. Reddys Lab 1287.20
Cipla 1347.65
Zydus Lifesciences 922.50
Lupin 2301.35
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×